Note 17 - Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2018 |
Notes Tables |
|
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] |
| |
| | | |
| | |
| | Deferred tax assets: | | | | | | | | | Net operating loss carryforwards | | $ | 29,597,313 | | | $ | 29,570,581 | | R&D credit carryforwards | | | 9,067,874 | | | | 10,043,714 | | AMT credit carryforward | | | 621,240 | | | | 1,229,979 | | Stock compensation | | | 375,731 | | | | 576,024 | | Intangibles | | | 550,797 | | | | 591,651 | | Gain/loss from discontinued operations | | | — | | | | (2,510,699 | ) | Disallowed interest expense | | | 878,929 | | | | — | | Temporary differences | | | 480,888 | | | | 207,447 | | Deferred tax assets before valuation allowance | | | 41,572,772 | | | | 39,708,697 | | Valuation allowance | | | (40,951,532 | ) | | | (38,478,718 | ) | Net deferred tax assets | | $ | 621,240 | | | $ | 1,229,979 | |
|
Summary of Tax Credit Carryforwards [Table Text Block] |
| | | | | | | | | | | | | | | 1999 | |
2019 | | $ | — | | | $ | 130,359 | | 2000 | |
2020 | | | — | | | | 71,713 | | 2001 | |
2021 | | | — | | | | 39,128 | | 2002 | |
2022 | | | — | | | | 5,350 | | 2003 | |
2023 | | | — | | | | 2,905 | | 2004 | |
2024 | | | — | | | | 22,861 | | 2005 | |
2025 | | | — | | | | 218,332 | | 2006 | |
2026 | | | — | | | | 365,541 | | 2007 | |
2027 | | | — | | | | 342,898 | | 2008 | |
2028 | | | — | | | | 531,539 | | 2009 | |
2029 | | | — | | | | 596,843 | | 2010 | |
2030 | | | — | | | | 1,094,449 | | 2011 | |
2031 | | | — | | | | 1,950,744 | | 2012 | |
2032 | | | 18,684,249 | | | | 468,008 | | 2013 | |
2033 | | | 37,450,522 | | | | 681,772 | | 2014 | |
2034 | | | 34,088,874 | | | | 816,116 | | 2015 | |
2035 | | | 25,073,846 | | | | 492,732 | | 2016 | |
2036 | | | 15,581,209 | | | | 262,257 | | 2017 | |
2037 | | | — | | | | 387,892 | | 2018 | | 2038 | | | — | | | | 197,547 | |
Total carryforwards | | $ | 130,878,700 | | | $ | 8,678,986 | |
|
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] |
| |
| | |
| | | |
| | |
| | |
| | |
| | Benefit at statutory rate | | $ | (3,383,491 | ) | | | (21.0 | )% | | $ | (6,048,423 | ) | | | (34.0 | )% | Adjustments to valuation allowance | | | 2,458,580 | | | | 15.3 | % | | | (26,080,051 | ) | | | (146.6 | )% | Adjustments to R&D credit carryforwards | | | 975,840 | | | | 6.1 | % | | | (291,745 | ) | | | (1.6 | )% | Tax law changes | | | — | | | | — | | | | 28,731,045 | | | | 161.5 | % | Permanent items and other | | | (60,682 | ) | | | (0.3 | )% | | | (373,315 | ) | | | (2.2 | )% | Benefit per financial statements | | $ | (9,753 | ) | | | | | | $ | (4,062,489 | ) | | | | |
|